Amylyx shares routed on skeptical adcomm docs — but did the FDA leave an open door on unmet ALS need?

Max Gelman

Senior Editor

The FDA released its briefing documents for Wednesday’s advisory committee to discuss Amylyx Pharmaceuticals’ ALS drug, and the initial impression appears to bode poorly for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Amylyx shares routed on skeptical adcomm docs — but did the FDA leave an open door on unmet ALS need?

Max Gelman

Senior Editor

Sign up to read this article for free.

Pfizer looking to sell hospital drugs unit — reports

AstraZeneca CEO reaffirms commitment to China following executive's detention

'Expertise is a real thing': FDA commissioner warns of political risk to agency

Merck, AstraZeneca tout Phase 3 win for cancer-turned-rare disease drug

Novartis pays $150M upfront to Schrödinger in new drug deal, ramps up software use

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Amy­lyx shares rout­ed on skep­ti­cal ad­comm docs — but did the FDA leave an open door on un­met ALS need?

Max Gelman

Senior Editor

Sign up to read this article for free.

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Amylyx shares routed on skeptical adcomm docs — but did the FDA leave an open door on unmet ALS need?

Pfizer looking to sell hospital drugs unit — reports

AstraZeneca CEO reaffirms commitment to China following executive's detention

'Expertise is a real thing': FDA commissioner warns of political risk to agency

Merck, AstraZeneca tout Phase 3 win for cancer-turned-rare disease drug

Novartis pays $150M upfront to Schrödinger in new drug deal, ramps up software use

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?